OPGN · Opgen Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q1 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $4.00M | - | - | - | $168.1K | $28.0K | - | $699.0K |
| Cost of Revenue | - | - | - | - | - | - | $73.2K | - | - | $618.8K |
| Gross Profit | - | - | - | - | - | - | $94.9K | - | - | $80.2K |
| R&D | - | - | - | - | - | $488 | $25.9K | $23.0K | - | $1.20M |
| SG&A | - | $701.9K | $594.8K | $513.3K | - | $768.6K | $1.64M | $1.57M | - | $2.03M |
| Total Operating Expenses | - | $702.2K | $597.2K | $522.8K | - | $783.9K | $1.87M | $1.58M | - | $4.26M |
| D&A | - | - | - | $46.0K | - | - | $138 | - | - | - |
| Operating Income | - | ($702.2K) | $3.40M | ($522.8K) | - | ($783.9K) | ($1.70M) | ($1.55M) | - | ($3.57M) |
| Interest Expense | - | $3.9K | $1.6K | $3.2K | - | $3.2K | $0 | $1.1K | - | $396.8K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($608.7K) | $3.51M | ($408.1K) | - | $8.93M | $386.0K | ($1.58M) | - | ($4.06M) |
| EPS - Basic | - | ($0.06) | $0.35 | ($0.04) | - | $1.43 | $0.21 | - | - | ($0.46) |
| EPS - Diluted | - | ($0.06) | ($1.18) | ($0.04) | - | $1.35 | $0.21 | - | - | ($0.46) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q1 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $531.3K | $414.2K | $831.6K | $1.11M | $1.31M | $1.63M | $2.16M | $470.4K | $1.15M | $292.6K |
| Accounts Receivable | $248.8K | $4.04M | $4.04M | $34.1K | $29.3K | $24.4K | $38.0K | $25.4K | $103.3K | $422.7K |
| Inventory | - | - | - | - | $1.23M | $1.23M | $1.28M | $1.23M | - | $2.81M |
| Accounts Payable | $1.08M | $307.8K | $297.9K | $311.6K | $245.2K | $103.9K | $191.6K | $128.4K | $111.1K | $904.6K |
| Current Assets | $988.2K | $5.52M | $6.12M | $2.24M | $2.65M | $3.22M | $532.6K | $572.8K | $1.58M | $3.45M |
| Total Assets | $38.06M | $12.64M | $13.24M | $9.42M | $9.86M | $5.47M | $2.97M | $2.87M | $1.88M | $18.13M |
| Current Liabilities | $4.55M | $782.5K | $827.2K | $563.5K | $634.2K | $589.8K | $11.70M | $12.60M | $11.42M | $12.47M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $4.85M |
| Total Liabilities | $6.20M | $2.48M | $2.58M | $2.36M | $2.48M | $2.48M | $13.68M | $14.54M | $13.44M | $15.46M |
| Stockholders' Equity | $31.86M | $10.16M | $10.67M | $7.05M | $7.38M | $2.99M | ($10.71M) | ($11.67M) | ($11.56M) | $2.68M |
| Retained Earnings | ($269.88M) | ($291.01M) | ($290.40M) | ($293.91M) | ($293.50M) | ($297.85M) | ($305.11M) | ($306.78M) | ($305.49M) | ($288.45M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q1 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($197.9K) | - | - | ($1.08M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | $199.7K | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q1 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 56.4% | - | - | 11.5% |
| Operating margin | - | - | 85.1% | - | - | - | -1012.9% | -5526.1% | - | -510.1% |
| EBITDA margin | - | - | - | - | - | - | -1012.8% | - | - | - |
| Net margin | - | - | 87.7% | - | - | - | 229.6% | -5629.8% | - | -581.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | 15.4% | 82.0% | - | 171.9% |
| SG&A / Revenue | - | - | 14.9% | - | - | - | 976.5% | 5602.2% | - | 291.1% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -4.8% | 26.5% | -4.3% | - | 163.3% | 13.0% | -54.9% | - | -22.4% |
| Return on equity | - | -6.0% | 32.9% | -5.8% | - | 299.1% | -3.6% | 13.5% | - | -151.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.22 | 7.06 | 7.39 | 3.97 | 4.18 | 5.46 | 0.05 | 0.05 | 0.14 | 0.28 |
| Quick ratio | 0.22 | 7.06 | 7.39 | 3.97 | 2.24 | 3.38 | -0.06 | -0.05 | 0.14 | 0.05 |
| Cash ratio | 0.12 | 0.53 | 1.01 | 1.97 | 2.07 | 2.77 | 0.18 | 0.04 | 0.10 | 0.02 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 1.81 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.27 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -179.3x | 2096.6x | -161.5x | - | -242.1x | - | -1434.0x | - | -9.0x |
| Equity multiplier | 1.19 | 1.24 | 1.24 | 1.34 | 1.34 | 1.83 | -0.28 | -0.25 | -0.16 | 6.78 |
| Liabilities / Assets | 0.16 | 0.20 | 0.19 | 0.25 | 0.25 | 0.45 | 4.61 | 5.07 | 7.14 | 0.85 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.30 | - | - | - | 0.06 | 0.01 | - | 0.04 |
| Inventory turnover | - | - | - | - | - | - | 0.06 | - | - | 0.22 |
| Days sales outstanding | - | - | 369d | - | - | - | 82d | 331d | - | 221d |
| Days inventory outstanding | - | - | - | - | - | - | 6383d | - | - | 1656d |
| Days payable outstanding | - | - | - | - | - | - | 955d | - | - | 534d |
| Cash conversion cycle | - | - | - | - | - | - | 5511d | - | - | 1343d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | 14185.7% | - | - | - | -81.6% | -96.2% | - | -43.6% |
| Revenue CAGR (3y) | - | - | 60.5% | - | - | - | -41.3% | -67.4% | - | -12.9% |
| Revenue CAGR (5y) | - | - | 27.5% | - | - | - | -30.3% | -51.2% | - | -1.3% |
| Gross profit growth (YoY) | - | - | - | - | - | - | -70.4% | - | - | -86.4% |
| Operating income growth (YoY) | - | 10.4% | - | 69.3% | - | 78.0% | 66.4% | 70.0% | - | 73.6% |
| Net income growth (YoY) | - | - | - | - | - | - | - | 72.9% | - | 71.2% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | -53.3% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 331.6% | 240.2% | - | - | - | 11.6% | - | - | - | -80.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$30.20M totalListing Sponsorship Services$30.20M · 100.0%
Geographic
$30.20M totalInternational$30.20M · 100.0%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing OPGEN INC against the 5 most active filers in the same SIC group.